News & Updates

Next-generation sequencing (NGS)–based analysis of circulating tumour DNA (ctDNA) helps predict benefit of second-line (2L) ripretinib or sunitinib therapy in patients with imatinib-resistant advanced gastrointestinal stromal tumours (GIST), an exploratory subanalysis of the INTRIGUE trial has shown.

Individuals who received radiation therapy for Hodgkin's lymphoma are at increased risk of colorectal cancer, as reported in a study.

A combination regimen comprising zolbetuximab and mFOLFOX6* chemotherapy (CT) regimen showed potential as first-line treatment for claudin-18.2-positive**/HER2-negative (CLDN18.2+/HER2–) locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, according to the primary findings of the phase III SPOTLIGHT trial.

Hormone therapy drugs, such as bicalutamide, flutamide, nilutamide, goserelin, degarelix, and apalutamide, appear to increase the likelihood of developing interstitial lung disease (ILD) events in patients with prostate cancer, reports a study.

The addition of bevacizumab (BVZ) to the standard regimen for the treatment of advanced colorectal cancer (CRC) appears to increase the risk of cardiovascular events, suggest the results of a meta-analysis presented at the recent ASCO Gastrointestinal Cancers Symposium (ASCO GI 2023).

Hypofractionated radiotherapy (HFRT) is not superior to conventionally fractionated radiotherapy (CFRT) in providing survival benefits to patients with stage I nonsmall cell lung cancer (NSCLC), but HFRT is preferable due to its convenience and lower costs, according to a study.

Adding the anti-PD-1 monoclonal antibody tislelizumab to chemotherapy in the first-line treatment of PD-1-positive advanced gastric or gastroesophageal junction adenocarcinoma appears to produce significant and clinically meaningful improvements in survival outcomes while having an acceptable safety profile, according to interim data from the phase III RATIONALE 305 trial.

Treatment with single fraction radiation therapy (RT) results in lesser hepatic pain in most patients with end-stage hepatocellular carcinoma (HCC) or liver metastases, according to a study presented at the recent ASCO Gastrointestinal Cancers Symposium (ASCO GI 2023).

Increased consumption of plant-based foods is associated with a lower risk of developing colorectal cancer (CRC) in men, according to the Multiethnic Cohort study.

Giving chemotherapy to patients with synchronous and unresectable liver metastases from colorectal cancer before undergoing primary tumour resection helps boost survival outcomes, according to a phase III trial presented at this year’s ASCO Gastrointestinal Cancer Symposium (ASCO GI).